Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.
Q2 2008 Financial Highlights

- Product sales up 40% to $706m

- Product sales excluding ADDERALL XR(R) up 64% to $409m

- New product sales(1) $243m, 34% of product sales (2007: 18%)

- Total revenues up 35% to $776m

- US GAAP earnings per ADS: loss $0.44 (2007: loss $9.93)

- Non GAAP earnings per ADS up 70% to $0.95 (2007: $0.56)

- Revenue guidance upgraded - 2008 revenue growth now expected to

be at least 20% (previous guidance: mid to high teens)

(1) New product sales comprise DAYTRANA, ELAPRASE, FOSRENOL, LIALDA /

MEZAVANT and VYVANSE

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver strong growth and broaden its business in specialty biopharmaceuticals. Our product sales for the quarter were up 40% on Q2 2007 with sales of new products now comprising 34% of total product sales. At $409m, product sales excluding ADDERALL XR were up 64% reflecting the success of our strategy to build a pipeline and portfolio for Shire's future growth.

"We are pleased with the performance of ELAPRASE, FOSRENOL, LIALDA, REPLAGAL and VYVANSE and are looking forward to the continued growth of VYVANSE in the US supplemented by the recent launch of the adult indication, the additional dosage strengths and the back-to-school season.

"We have decided to commence a phased discontinuation of DYNEPO. Resources supporting this product will be re-directed to faster growing, profitable core global products.

"The proposed acquisition of Jerini AG in Germany, which we expect to complete in Q3, is an excellent match for our business and we expect to benefit from both its near term revenues and long term growth. The recent EU approval of Je
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  In recognition of World ... with hemophilia advocacy groups to illuminate more than 15 prominent ... including Boston,s Zakim Bridge and Prudential ... New Orleans, Mercedes-Benz Superdome and Denver,s ... during the evening of April 17, and coincide with hemophilia ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... The state of the microRNA market and the molecule,s, ... diagnostics, ... - TIME: 3 pm EDT, ... Christi Bird, Senior Research Analyst, Healthcare, ...
... Ear Diseases to Guide Novel Treatments to ClinicSAN ... its scientific advisory board comprised of physicians and ... the ear. The advisory board includes three of ... Harris, M.D., Ph.D.; and Allen Ryan, Ph.D. Joining ...
... leading campus recruitment company, has announced the official ... new website is designed for students, recent graduates, ... the biotechnology, pharmaceutical, and life sciences industries. With ... more people are considering a career in these ...
Cached Biology Technology:Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics 2Otonomy Introduces Scientific Advisory Board 2Otonomy Introduces Scientific Advisory Board 3Otonomy Introduces Scientific Advisory Board 4Otonomy Introduces Scientific Advisory Board 5Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 2Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 3
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... In the first study of its kind, researchers ... have found that low socioeconomic status (SES) and maternal ... of attention deficit hyperactivity disorder (ADHD) in six year ... of the Archives of Pediatrics and Adolescent Medicine ...
... Northeast Public Radio and the Cary Institute of Ecosystem Studies ... look at our changing environment. The collaboration was formed to ... raising awareness about the science that underpins environmental issues. ... 11:10 AM and 4:04 PM on WAMC. With the ...
... in German . , Many animals produce ... kin or mates are present than other audience members. So ... the other group members, knowledge state into account. Researchers from ... and the University of St. Andrews, Great Britain, set up ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2Cary Institute and WAMC debut new environment radio show 2I know something you don't know -- and I will tell you! 2
... of Wyatt Technology's family of light scattering ... high temperature chromatograph and enables you to ... polymers. The HTmD is easily installed in ... or Alliance 2000 device and enables you ...
...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. ... GAS. A cell-permeable sulfanamido-benzbromarone compound that ... non-competitive allosteric inhibitor of PTP1B (IC ... 8 μM for PTP1B 403 ...
... White walled plates enhance luminescent ... and fluorescence,• Not treated (or medium ... nature and binds biomolecules through passive ... immobilization of large molecules, such as ...
Biology Products: